SCHEMBL23620156

SCHEMBL23620156

COc1nc(OCC(F)F)c(F)cc1N

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 3/20 0.35
SCN9A Q15858 3/20 0.34
SCN5A Q14524 1/20 0.34
MAPT P10636 1/20 0.33
CASP1 P29466 1/20 0.33
AURKA O14965 1/20 0.33
TTK P33981 1/20 0.33
AURKB Q96GD4 1/20 0.33
INCENP Q9NQS7 1/20 0.33
PIK3CD O00329 1/20 0.31
PIK3CG P48736 1/20 0.31
MBOAT4 Q96T53 2/20 0.31
TAAR1 Q96RJ0 1/20 0.31
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
ALDH1A1 P00352 1/20 0.30
RAB9A P51151 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30727419 1.00 PIK3CA (0.35) PIK3CASCN9ASCN5AMAPTCASP1
SCHEMBL30727422 1.00 PIK3CA (0.35) PIK3CASCN9ASCN5AMAPTCASP1
SCHEMBL23620104 0.83 PIK3CA (0.40) PIK3CAMAPTCASP1AURKATTK
SCHEMBL29830183 0.82 SCN5A (0.33) SCN9ASCN5AMBOAT4
SCHEMBL23620105 0.82 SCN5A (0.33) SCN9ASCN5AMBOAT4
SCHEMBL21596671 0.81 PIK3CA (0.33) PIK3CAMAPTCASP1AURKATTK
SCHEMBL30991286 0.81 PIK3CA (0.33) PIK3CAMAPTCASP1AURKATTK
SCHEMBL23620201 0.79 PIK3CA (0.35) PIK3CAMAPTCASP1AURKATTK
SCHEMBL22824335 0.79 PIK3CA (0.34) PIK3CASCN9AMAPTCASP1AURKA
SCHEMBL30977384 0.77 SCN9A (0.37) PIK3CASCN9ASCN5AMAPTPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027104-A1 NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2026-01-29 US disclosed
US-20250296931-A1 NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2025-09-25 US disclosed
EP-4558479-A1 NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-05-28 EP disclosed
EP-4558498-A1 NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-05-28 EP disclosed
US-11939319-B2 Pyridinyl and pyrazinyl-(asa)indolsulfonamides UCB PHARMA GMBH (DE) 2024-03-26 US disclosed
US-11939319-B2 Pyridinyl and pyrazinyl-(asa)indolsulfonamides UCB PHARMA GMBH (DE) 2024-03-26 US disclosed
US-11939319-B2 Pyridinyl and pyrazinyl-(asa)indolsulfonamides UCB PHARMA GMBH (DE) 2024-03-26 US disclosed
WO-2024017858-A1 NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-01-25 WO disclosed
WO-2024017856-A1 NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-01-25 WO disclosed
WO-2024017857-A1 NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-01-25 WO disclosed
WO-2024017857-A1 NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-01-25 WO disclosed
WO-2024017856-A1 NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-01-25 WO disclosed
WO-2024017858-A1 NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-01-25 WO disclosed
EP-4074703-B1 PYRIDINYL-(AZA)INDOLSULFONAMIDES UCB PHARMA GMBH (DE) 2023-11-29 EP disclosed
EP-4074703-B1 PYRIDINYL-(AZA)INDOLSULFONAMIDES UCB PHARMA GMBH (DE) 2023-11-29 EP disclosed
EP-4074703-A1 PYRIDINYL-(AZA)INDOLSULFONAMIDES UCB Pharma GmbH (DE) 2022-10-19 EP disclosed
EP-4074703-A1 PYRIDINYL-(AZA)INDOLSULFONAMIDES UCB Pharma GmbH (DE) 2022-10-19 EP disclosed
EP-3810591-B1 PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES UCB PHARMA GMBH (DE) 2022-08-10 EP disclosed
US-20210206749-A1 Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides UCB PHARMA GMBH (DE) 2021-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296931-A1 NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES SULT1E1, XDH, PRXL2A PIK3CA 637/4885SCN9A 2611/4885SCN5A 994/4885
US-20260027104-A1 NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES CBR3, HAX1, CBR1 PIK3CA 3320/4885SCN9A 315/4885SCN5A 435/4885
US-20210206749-A1 Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides GPR17, GPR18, GPR119 PIK3CA 2852/4885SCN9A 2844/4885SCN5A 1480/4885
US-11939319-B2 Pyridinyl and pyrazinyl-(asa)indolsulfonamides GPR17, GPR18, GPR119 PIK3CA 2852/4885SCN9A 2844/4885SCN5A 1480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.